| Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study. | |
| | |
MedLine Citation:
|
PMID: 22412041 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
BACKGROUND: To measure bone mineral density (BMD) reduction produced by letrozole as compared with tamoxifen and the benefit of the addition of zoledronic acid. PATIENTS AND METHODS: A phase 3 trial comparing tamoxifen, letrozole or letrozole + zoledronic acid in patients with hormone receptor-positive early breast cancer was conducted; triptorelin was given to premenopausal patients. Two comparisons were planned: letrozole versus tamoxifen and letrozole + zoledronic acid versus letrozole. Primary end point was the difference in 1-year change of T-score at lumbar spine (LTS) measured by dual energy X-ray absorptiometry scan. RESULTS: Out of 483 patients enrolled, 459 were available for primary analyses. Median age was 50 (range 28-80). The estimated mean difference (95% confidence interval [CI]) in 1-year change of LTS was equal to -0.30 (95% CI -0.44 to -0.17) in the letrozole versus tamoxifen comparison (P < 0.0001) and to +0.60 (95% CI +0.46 to +0.77) in the letrozole + zoledronic acid versus letrozole comparison (P < 0.0001). Bone damage by letrozole decreased with increasing baseline body mass index in premenopausal, but not postmenopausal, patients (interaction test P = 0.004 and 0.47, respectively). CONCLUSIONS: In the HOBOE (HOrmonal BOne Effects) trial, the positive effect of zoledronic acid on BMD largely counteracts damage produced by letrozole as compared with tamoxifen. Letrozole effect is lower among overweight/obese premenopausal patients. |
| | |
Authors:
|
F Nuzzo; C Gallo; S Lastoria; M Di Maio; M C Piccirillo; A Gravina; G Landi; E Rossi; C Pacilio; V Labonia; F Di Rella; A Bartiromo; G Buonfanti; G De Feo; G Esposito; R D'Aniello; P Maiolino; S Signoriello; E De Maio; V Tinessa; G Colantuoni; M De Laurentiis; M D'Aiuto; M Di Bonito; G Botti; P Giordano; G Daniele; A Morabito; N Normanno; A de Matteis; F Perrone |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-3-12 |
Journal Detail:
|
Title: Annals of oncology : official journal of the European Society for Medical Oncology / ESMO Volume: - ISSN: 1569-8041 ISO Abbreviation: - Publication Date: 2012 Mar |
Date Detail:
|
Created Date: 2012-3-13 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9007735 Medline TA: Ann Oncol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Medical Oncology, Department of Senology, National Cancer Institute, Napoli. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Prolonged Versus Standard Duration Venous Thromboprophylaxis in Major Orthopedic Surgery: A Systemat...
Next Document: Male patients with partial androgen insensitivity syndrome: a longitudinal follow-up of growth, repr...